NANOG and breast carcinoma: We therefore proposed that it is possible that Ugonin J treatment causes concomitant downregulation of beta-catenin and NANOG in breast cancer, but, in absence of wnt/beta-catenin, ugonin J is capable to downregulate NANOG expression through p53 activation.